Samsung Biologics has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Samsung Biologics will provide a full scope of development services from cell line development, process development, to non-clinical and clinical material manufacturing. PB101 is being developed to suppress tumor angiogenesis more effectively by targeting VEGF-A and PlGF simultaneously, overcoming the limitations of existing treatments. Leveragi...